182 related articles for article (PubMed ID: 29137963)
1. Failure of a second temozolomide cycle in a patient with a prolactin-secreting pituitary carcinoma.
Bilbao I; Egaña N; García C; Olaizola I
Endocrinol Diabetes Nutr; 2017 Dec; 64(10):564-566. PubMed ID: 29137963
[No Abstract] [Full Text] [Related]
2. Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment.
Philippon M; Morange I; Barrie M; Barlier A; Taieb D; Dufour H; Conte-Devolx B; Brue T; Castinetti F
Ann Endocrinol (Paris); 2012 Jun; 73(3):225-9. PubMed ID: 22520146
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of a child with a prolactin secreting macroadenoma with temozolomide.
Felker J; Patterson B; Wrubel D; Janss A
J Pediatr Endocrinol Metab; 2016 Dec; 29(12):1413-1415. PubMed ID: 27815961
[TBL] [Abstract][Full Text] [Related]
4. Prolactinomas.
Couldwell WT; Weiss MH; Laws ER
N Engl J Med; 2004 Mar; 350(10):1054-7; author reply 1054-7. PubMed ID: 15002121
[No Abstract] [Full Text] [Related]
5. Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings.
Kovacs K; Horvath E; Syro LV; Uribe H; Penagos LC; Ortiz LD; Fadul CE
Hum Pathol; 2007 Jan; 38(1):185-9. PubMed ID: 17056093
[TBL] [Abstract][Full Text] [Related]
6. Long-term response of pituitary carcinoma to temozolomide. Report of two cases.
Fadul CE; Kominsky AL; Meyer LP; Kingman LS; Kinlaw WB; Rhodes CH; Eskey CJ; Simmons NE
J Neurosurg; 2006 Oct; 105(4):621-6. PubMed ID: 17044568
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response.
Strowd RE; Salvatori R; Laterra JJ
J Oncol Pharm Pract; 2016 Jun; 22(3):517-22. PubMed ID: 25616657
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of leptomeningeally metastasised pituitary carcinoma with temozolomide.
van der Vlist A; Snijders TJ; Stades AME; Spliet WGM; De Vos FYFL
Neth J Med; 2017 Dec; 75(10):451-454. PubMed ID: 29256415
[TBL] [Abstract][Full Text] [Related]
9. What causes a prolactinoma to be aggressive or to become a pituitary carcinoma?
Phillips J; East HE; French SE; Melcescu E; Hamilton RD; Nicholas WC; Fratkin JF; Parent AD; Luzardo G; Koch CA
Hormones (Athens); 2012; 11(4):477-82. PubMed ID: 23422771
[TBL] [Abstract][Full Text] [Related]
10. A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.
Murakami M; Mizutani A; Asano S; Katakami H; Ozawa Y; Yamazaki K; Ishida Y; Takano K; Okinaga H; Matsuno A
Neurosurgery; 2011 Jun; 68(6):E1761-7; discussion E1767. PubMed ID: 21389894
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.
Lasolle H; Cortet C; Castinetti F; Cloix L; Caron P; Delemer B; Desailloud R; Jublanc C; Lebrun-Frenay C; Sadoul JL; Taillandier L; Batisse-Lignier M; Bonnet F; Bourcigaux N; Bresson D; Chabre O; Chanson P; Garcia C; Haissaguerre M; Reznik Y; Borot S; Villa C; Vasiljevic A; Gaillard S; Jouanneau E; Assié G; Raverot G
Eur J Endocrinol; 2017 Jun; 176(6):769-777. PubMed ID: 28432119
[TBL] [Abstract][Full Text] [Related]
12. Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm.
Syro LV; Uribe H; Penagos LC; Ortiz LD; Fadul CE; Horvath E; Kovacs K
Clin Endocrinol (Oxf); 2006 Oct; 65(4):552-3. PubMed ID: 16984254
[No Abstract] [Full Text] [Related]
13. [Recurrence of prolactinoma surveyed. Hormone therapy can safely be withdrawn for a long time in patients with normalized prolactin levels and invisible tumor].
Werner S
Lakartidningen; 2004 Oct; 101(41):3162-3. PubMed ID: 15517713
[No Abstract] [Full Text] [Related]
14. Evolution of a prolactin-secreting pituitary microadenoma into a fatal carcinoma: a case report.
Guastamacchia E; Triggiani V; Tafaro E; De Tommasi A; De Tommasi C; Luzzi S; Sabbà C; Resta F; Terreni MR; Losa M
Minerva Endocrinol; 2007 Sep; 32(3):231-6. PubMed ID: 17912159
[TBL] [Abstract][Full Text] [Related]
15. [Pituitary apoplexy in a pregnant woman with cystic microprolactinoma].
Querol Ripoll R; Cámara Gómez R; Del Olmo García M; Simal Julián JA; Merino Torres JF
Endocrinol Nutr; 2015 Apr; 62(4):200-2. PubMed ID: 25732323
[No Abstract] [Full Text] [Related]
16. Prolactin secreting pituitary carcinoma.
Petterson T; MacFarlane IA; MacKenzie JM; Shaw MD
J Neurol Neurosurg Psychiatry; 1992 Dec; 55(12):1205-6. PubMed ID: 1479402
[TBL] [Abstract][Full Text] [Related]
17. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients.
Ono M; Miki N; Kawamata T; Makino R; Amano K; Seki T; Kubo O; Hori T; Takano K
J Clin Endocrinol Metab; 2008 Dec; 93(12):4721-7. PubMed ID: 18812485
[TBL] [Abstract][Full Text] [Related]
18. Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date.
Chen C; Yin S; Zhang S; Wang M; Hu Y; Zhou P; Jiang S
Medicine (Baltimore); 2017 Nov; 96(47):e8733. PubMed ID: 29381964
[TBL] [Abstract][Full Text] [Related]
19. A novel use of temozolomide in a patient with malignant prolactinoma.
Byrne S; Karapetis C; Vrodos N
J Clin Neurosci; 2009 Dec; 16(12):1694-6. PubMed ID: 19818629
[TBL] [Abstract][Full Text] [Related]
20. Demographic characteristics, presentations and treatment outcome of patients with prolactinoma.
Malik S; Hussain SZ; Basit R; Idress N; Habib A; Zamant M; Islam N
J Ayub Med Coll Abbottabad; 2014; 26(3):269-74. PubMed ID: 25671924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]